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Cerebral blood flow (CBF) and consequently orthostatic tolerance when upright depends 
on dilation of the cerebral vasculature in the face of reduced perfusion pressure asso-
ciated with the hydrostatic gradient. However, it is still unclear if cholinergic activation 
plays a role in this dilation. To determine if enhancing central cholinergic activity with the 
centrally acting acetylcholinesterase inhibitor, physostigmine would increase CBF when 
upright compared to the peripherally acting acetylcholinesterase inhibitor, neostigmine, 
or saline. We performed a randomized double-blind dose-ranging study that took place 
over 3 days in a hospital-based research lab. Eight healthy controls (six women and two 
men, mean age, 26 years; range 21–33) were given infusions of physostigmine, neostig-
mine, or saline on three different days. Five-minute tilts were repeated at baseline (no 
infusion), Dose 1 (0.2 μg/kg/min physostigmine; 0.1 μg/kg/min neostigmine) and Dose 2 
(0.6 μg/kg/min physostigmine or 0.3 μg/kg/min neostigmine), and placebo (0.9% NaCl). 
Cerebral blood velocity, beat-to-beat blood pressure, and end-tidal CO2 were continu-
ously measured during tilts. Physostigmine (0.6 μg/kg/min) resulted in higher cerebral 
blood velocity during tilt (90.5 ± 1.5%) than the equivalent neostigmine (85.5 ± 2.6%) or 
saline (84.8 ± 1.7%) trials (P < 0.05). This increase occurred despite a greater postural 
hypocapnia, suggesting physostigmine had a direct vasodilatory effect on the cerebral 
vasculature. Cerebral hypoperfusion induced by repeated tilts was eliminated by infusion 
of physostigmine not neostigmine. In conclusion, this study provides the first evidence 
that enhancement of central, not peripheral, cholinergic activity attenuates the physio-
logical decrease in CBF seen during upright tilt. These data support the need for further 
research to determine if enhancing central cholinergic activity may improve symptoms in 
patients with symptomatic orthostatic intolerance.
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inTrODUcTiOn
Orthostatic intolerance, which includes symptoms of lightheadedness, weakness, dizziness and 
presyncope, is a consequence of the inability to maintain cerebral perfusion when upright (1). While 
the peripheral vascular responses to orthostatic stress are well characterized, the cerebrovascular 
response is less clearly understood.
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The upright posture results in a reduction in cerebral perfu-
sion pressure due to the hydrostatic gradient (2), and thus 
cerebral resistance vessels must dilate to maintain cerebral blood 
flow (CBF). An inadequate dilatory response would impair flow. 
In fact, healthy individuals that develop orthostatic intolerance 
demonstrate greater decreases in CBF (3, 4), even when arterial 
pressure is maintained (4), suggesting cerebral vasoconstriction 
or inadequate cerebral vasodilation is present. The role of cer-
ebral hypoperfusion in orthostatic intolerance patients of diverse 
causes remains unclear. Some studies have demonstrated greater 
decreases in CBF (3, 5) while others have not (6).
Cerebral vessels are densely innervated by parasympathetic 
nerves (7, 8) that could play a direct vasoregulatory role. Recently, 
it has been proposed that cholinergic activation could play an 
important role in control of the cerebral vasculature (9). Both 
animal (wide range of quadrupeds), primate and human studies 
have implicated parasympathetic nerves in cerebral vasodilation 
(7, 10, 11). Although several neurotransmitters are involved, 
there is evidence in humans that acetylcholinesterase inhibition 
leads to an increase in CBF without a change in metabolism while 
supine (12), supporting a direct vasodilatory role for cholinergic 
nerves. However, there are no reports on the role of the choliner-
gic system on CBF when upright.
To examine the role of the cholinergic system in cerebral vaso-
dilation in healthy control participants during orthostatic stress, 
we administered the centrally acting, tertiary amine, cholinest-
erase inhibitor, physostigmine to enhance central cholinergic 
activity during orthostatic stress to determine if the CBF response 
to upright tilt would be improved. To control for the effects of 
increased peripheral cholinergic activity, we administered the 
quaternary amine, cholinesterase inhibitor, neostigmine, which 
does not cross the blood brain barrier. We hypothesized that 
cholinergic cerebral vasodilation would increase CBF in the 
upright posture.
MaTerials anD MeThODs
All procedures were approved by Beth Israel Deaconess Medical 
Center Committee on Clinical Investigations. All participants 
were consented by Dr. Jorge Serrador prior to participation in 
the study. Participants were given the consent form and the 
opportunity to read it. Then procedures were verbally explained 
by Dr. Serrador, and they were asked if they had any questions 
or concerns. After verbal confirmation was received that they 
understand the procedures and risks, they signed the consent 
form, and it was witnessed.
Participants
Participants had no history of cardiopulmonary, renal, neurologi-
cal or other systemic disease. Caffeine, alcohol, and heavy exercise 
were prohibited for 24 h prior to testing. A medical history, physi-
cal exam, and pregnancy test were performed on all participants.
Drug Dosage
Testing was double blind with participants returning on three 
separate occasions, with the drug received on each testing day 
randomly determined (saline, neostigmine, and physostigmine). 
Drugs were mixed at the research pharmacy and provided in an 
unlabeled bag so that study staff and participants were blind to 
what infusion was being performed. Each test day consisted of 
baseline and three dosage levels: baseline (no infusion), Dose 1 
(0.2 μg·kg−1·min−1 physostigmine; 0.1 μg·kg−1·min−1 neostigmine), 
Dose 2 (0.6  μg·kg−1·min−1 physostigmine or 0.3  μg·kg−1·min−1 
neostigmine), and Dose 3 (1.0 μg·kg−1·min−1 physostigmine or 
0.5 μg·kg−1·min−1 neostigmine) or placebo (0.9% NaCl) for all 
three infusion levels (Figure 1).
cerebrovascular reactivity
Cerebrovascular reactivity was assessed while breathing 8% CO2, 
21% O2, balance nitrogen, and mildly hyperventilating for 2 min 
each. Two minute periods were chosen since previous work 
found the time constant for cerebral flow velocity responses to 
changes in end-tidal CO2 is ~45 s (13). Thus, the first 60 s allow for 
adaptation to the stimulus, and the second 60 s can assess steady 
state response. In addition, recent research has found that sus-
tained hypercapnia or hypocapnia can result in changes in MCA 
diameter, but only after continual steady state periods longer than 
2 min (14). Thus, using 2 min periods allows for assessing velocity 
changes without associated diameter changes.
Tilt Testing
Each test session comprised four 5-min tilts (60°) preceded by 
10 min supine rest and followed by 5 min of recovery. Following 
each recovery period, the infusion was increased so that partici-
pants received a total of three dose levels and four tilts (Figure 1). 
Participants remained upright for 5 min or until they developed 
presyncopal symptoms. Five-minute tilts with a 15 min supine 
recovery between tilts were used in order to complete all dosage 
levels within one session and to minimize the effect of repeated 
tilts on orthostatic tolerance. A prior report suggests that six 
repeated 10 min tilts with 30 s supine in between results in reduced 
orthostatic tolerance (15). Heart rate (HR) (Datex Cardiocap 
II), beat-to-beat blood pressure (BP) (Finometer), cerebral flow 
velocity in the middle cerebral (CFVMCA), and anterior cerebral 
(CFVACA) arteries (transcranial Doppler, Multi-Dop X4), and 
end-tidal CO2 (Datex-Ohmeda) was continuously recorded.
Data Analysis
Signals were sampled at 500  Hz and processed using data 
acquisition (WinDaq) and analysis (MATLAB) software. 
Cerebrovascular reactivity was determined by plotting cerebral 
flow velocity vs end-tidal CO2 during testing including a 6  s 
delay between end-tidal and flow velocity changes. Plots were 
created of breath-by-breath end-tidal CO2 vs CFV was created 
over both the baseline, hypercapnia and hypocapnia periods. 
Cerebrovascular reactivity was determined as the linear best fit 
for the data.
BPbrain (BP at heart level minus hydrostatic gradient) was used 
to reflect cerebral perfusion pressure since intracranial pressure 
remains relatively unchanged (2). CFV was normalized to base-
line (supine rest prior to first tilt) to better reflect changes in CBF 
(16). Estimated cerebrovascular resistance (CVR) was derived by 
dividing BPbrain by CFV. To minimize probe placement effects, 
TCD operators and probe depths were kept constant.
FigUre 1 | Protocol diagram for physostigmine, neostigmine, saline infusion. Protocol for each study session. Participants underwent four tilts consisting of 
10 min supine, 5 min tilt, and 5 min recovery. Following each recovery period, infusion was started or increased (every 20 min). Participants were randomly assigned 
to drug condition, and infusions were performed in a double-blind fashion. Infusion doses are shown for each drug condition (neostigmine and physostigmine) and 
placebo control (saline).
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statistics
To examine the role of cholinergic activity on the cerebrovascular 
response to tilt, comparisons were made between drugs as well 
as dose and body position, i.e., supine vs upright. A three-way 
repeated-measures ANOVA was performed (Drug × Dose × Tilt), 
with a Bonferroni post hoc analysis. Mean values during last 3 min 
of tilt were compared to baseline (mean of last 5 min supine prior 
to tilt). Data are presented as mean ± SEM, p < 0.05 considered 
significant.
resUlTs
Participant characteristics
Eight participants (6 women and 2 men, mean age, 26  years; 
range 21–33 years, 67.7 ± 15.2 kg, 166.7 ± 4.7 cm, mean ± SD) 
completed 12 tilts over 3 visits without developing presyncope.
effect of repeated Orthostatic stress 
during saline infusion
Blood pressure while upright was similar during all tilts as was 
HR (Figures 2 and 3, open circles). Repeated orthostatic stress 
resulted in significantly reduced cerebral flow velocity while 
upright during Tilt 3 (Figure  4). It also resulted in slightly 
reduced end-tidal CO2 during the third tilt compared to the first 
(<1 mmHg difference), see Table 1.
effect of acetylcholinesterase inhibitors 
on the Orthostatic response
Neostigmine
Supine BP and end-tidal CO2 were unaffected by dosage level 
during the 5 min prior to tilt (Table 1). In contrast, CFV in both 
arteries demonstrated a small but significant increase at Dose 2 
while HR decreased during the same supine period. During tilt 
at Dose 2, neostigmine resulted in lower cerebral flow velocity 
as well as lower HRs (Figure  2) and slightly lower end-tidal 
CO2  (<1  mmHg, Table  1). Lower cerebral blood flow velocity 
and end-tidal CO2 were also seen during the third tilt with 
saline infusion, and thus these changes may be have been due 
to repeated tilts rather than neostigmine. Mean arterial pressure 
(MAP), when upright, was unaffected by dosage but diastolic BP 
increased. During Dose 3, the trial was stopped in one participant 
due to the development of nausea.
Physostigmine
Supine BP, end-tidal CO2 and cerebral flow velocity were unaf-
fected by dose level during the 5 min prior to tilt (Figure 2 and 
Table 1). In contrast, CFV and HR increased at Dose 2. During 
tilt at Dose 2, cerebral flow velocity values were higher compared 
to baseline tilt (Figure 2). This increased CBF velocity occurred 
despite there being no difference between baseline and Dose 2 
tilts in BP or HR. Similar to saline and neostigmine, end-tidal 
CO2 was slightly lower during Dose 2 compared to baseline tilt 
(<1  mmHg, Table  1). The increase in CFV was present across 
arterial territories (i.e., both middle and anterior cerebral arter-
ies) and during supine recovery (Figure 4).
Cerebrovascular resistance decreased during tilt in all condi-
tions (Table 1) but not sufficiently to maintain flow at baseline lev-
els. Since CVR changes are due to both autoregulatory responses 
to pressure changes and neurogenic vasoregulation, we exam-
ined the non-autoregulatory component of the CVR response 
(CVRNA). This was determined by subtracting the autoregulatory 
CVR (CVR necessary to maintain 100% of baseline flow during 
pressure changes) from the actual CVR obtained during each 
tilt. Since measures of autoregulation (transfer function gains) 
demonstrated no changes with infusion (data not shown), we 
assumed autoregulation was intact. Comparison of the upright 
response during the first three tilts demonstrated that in contrast 
FigUre 2 | cardiovascular response to tilt during physostigmine, neostigmine, and saline infusion. Changes in mean cerebral flow velocity for both 
arteries (CFV), blood pressure corrected to brain level (BPbrain), and heart rate (HR) from supine (mean of 6–10 min) to 60° head up tilt during infusion of saline (white), 
neostigmine (gray), or physostigmine (black) at Baseline (no infusion), Dose 1, and Dose 2. *A significant difference from baseline supine values (P < 0.05). 
†Significantly lower CFV while upright compared to Tilt 1 for saline and neostigmine only (P < 0.05). αSignificant effect of drug at that dose (P < 0.05). All tilt values 
were significantly different from supine (P < 0.005).
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to the saline and neostigmine Dose 2 tilts where CVRNA was 
greater, during Dose 2 physostigmine CVRNA was lower, sug-
gesting improved vasodilation, which would explain the better 
maintenance of cerebral flow velocity (Figure  3). In addition 
this would suggest that the physostigmine was able to counteract 
the detrimental effect of repeated tilts that resulted in reduced 
flow velocity and increased resistance during Tilt 3 in the saline 
and neostigmine groups. Dose 3 of the physostigmine trial was 
terminated in seven of eight participants due to the development 
of nausea and thus was not included in the analysis.
response of regional cBF
Examination of middle cerebral and anterior cerebral artery 
velocity demonstrated that both arteries had similar changes 
associated with repeated tilt for both neostigmine and physostig-
mine (Figure  4). Decreases in middle cerebral artery velocity 
tended to be greater than those seen in the anterior cerebral artery 
during both repeated saline and neostigmine tilts, although this 
trend did not reach significance. Interestingly, middle cerebral 
artery velocity was improved during both Dose 1 and Dose 
2 of physostigmine in the last minute of tilt (Figure  5). Probe 
placement was consistent across days; no difference in cerebral 
flow velocity during first baseline, regardless of trial (P = 0.80). 
Cerebrovascular reactivity was not significantly different between 
trials (P = 0.50) and did not differ between arteries (P = 0.70).
DiscUssiOn
This study provides the first evidence that enhancement of 
central, not peripheral, cholinergic activity attenuates the physi-
ological decrease in CBF seen during upright tilt. We also found 
that enhancing central cholinergic activity (via physostigmine) 
attenuates the decrease in CBF associated with repeated exposure 
to short duration orthostatic stress.
Assumption of the upright posture is associated with 
a number of adaptations to maintain arterial pressure in 
response to translocation of blood in the dependent circula-
tion. Parasympathetic activity is attenuated, and sympathetic 
FigUre 3 | non-autoregulatory response to infusion. The non-autoregulatory cerebrovascular resistance (CVRNA), blood pressure corrected to brain level (BPbrain), 
and end-tidal CO2 (PETCO2) response to 5 min of 60° head up tilt during infusion of saline (white), neostigmine (gray), or physostigmine (black) at Baseline, Dose 1, and 
Dose 2. †Significantly higher CVRNA while upright compared to Tilt 1 for saline and neostigmine only (P < 0.05). αIndicates significant effect of drug at that dose (P < 0.05).
FigUre 4 | regional cerebral blood flow response to infusion. Anterior 
cerebral artery (ACA) and middle cerebral artery (MCA) cerebral flow velocity 
(CFV) response during 5 min of 60° head up tilt during saline infusion and 
during Dose 1 and Dose 2 infusion of either neostigmine or physostigmine. 
There were no significant differences between arteries in responses to either 
dosage or drug. *A significant difference from baseline tilt values (P < 0.05). 
αSignificant effect of drug at that dose (P < 0.05).
5
Serrador and Freeman Cholinergic Activity Increases CBF
Frontiers in Neurology | www.frontiersin.org March 2017 | Volume 8 | Article 103
outflow increases, leading to increased HR and peripheral 
vasoconstriction to maintain arterial pressure. In addition, 
the cerebral vasculature is now above the heart, and perfusion 
pressure is reduced ~20 mmHg (2). Thus, to maintain CBF in 
the upright position, cerebral vessels must dilate. If cerebral 
vessels are unable to dilate and cerebral hypoperfusion occurs, 
syncope will result.
Several animal models provide evidence that parasympathetic 
pathways are implicated in cerebral vasodilation (7, 10). Studies 
document that parasympathetic activation causes increased CBF 
independent of metabolism suggesting a direct vasodilatory role 
(10, 17). Similarly removal of the pterygopalatine ganglion inter-
rupts parasympathetic pathways and causes reductions in CBF 
in rats (18). In addition, enhancement of cholinergic activity 
using physostigmine improves the functional increase in CBF 
in the somatosensory cortex during vibrotactile stimulation 
[determined by positron emission tomography (PET)] in elderly 
monkeys (19). Similarly, in young-adult monkeys, impairing 
cholinergic activity using scopolamine abolishes the functional 
increase in CBF during vibrotactile stimulation and enhancing 
cholinergic activity via physostigmine reinstates it. In humans, 
several lines of evidence suggest a role for cholinergic inputs. For 
example, regional CBF, as measured by PET or SPECT, increases 
during stimulation of the vagus nerve (11, 20) or inhibition of 
acetylcholinesterase with physostigmine (12, 21–24). While flow 
increased with physostigmine in these studies, metabolism was 
unchanged (12), further supporting a direct vasodilatory effect. 
There is also evidence that administration of scopolamine causes 
a decrease in CBF that is reversed by physostigmine but not 
neostigmine, supporting a role for central cholinergic regulation 
of CBF (25). Neostigmine, which does not cross the blood brain 
barrier, also did not improve the CBF response in our studies. 
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While some work has found no change in CBF with physostig-
mine administration (21), or decreases in global CBF in healthy 
controls (26), the later study also reported a tendency for global 
CBF to increase in veterans with Gulf War Illness and cogni-
tive dysfunction. Veterans with Gulf War Illness have also been 
found to have cholinergic autonomic dysfunction (27). Thus, 
the increase in CBF with physostigmine infusion while supine 
in these veterans may have been the result of the physostigmine 
enhancing cholinergic activity from impaired to normal levels. 
Further work in this group would be necessary to confirm this.
However, one important differentiation between the current 
work and all of the previous work mentioned was that none of the 
previous studies have examined the upright response. Without 
this orthostatic stress, the improvement in CBF with cholinergic 
enhancement would have been missed.
Consistent with previous work (15), we found that repeated 
tilts (in both the saline and neostigmine conditions) caused a 
greater reduction in CBF when upright and increased CVR (see 
Tilt 3, Figures 2 and 3). In contrast, during physostigmine infu-
sion, there was increased CBF compared to previous tilts. Thus, 
the increase in CBF during Tilt 3 with physostigmine infusion 
occurred despite the parallel detrimental effect of repeated tilts 
on cerebral perfusion. Furthermore, physostigmine also attenu-
ated the greater cerebral hypoperfusion during supine recovery 
(Table 1). However, the mechanism for this detrimental effect of 
repeated orthostatic stress remains unknown.
While our data demonstrate that pharmacological enhance-
ment of central cholinergic activity improves CBF during 
orthostasis, it is not known whether there is physiological 
activation of the central cholinergic system during orthos-
tatic stress; particularly since peripheral cholinergic activity 
decreases during orthostatic stress. Several lines of evidence 
support differential autonomic outflow to individual vascular 
beds, for example, sympathetic activation causes mesenteric 
vasoconstriction with hindquarter vasodilation in rats (28) and 
femoral vasoconstriction without affecting CVR in humans 
(29). These data lend some support to the possibility that there 
is a physiological increase in cerebral cholinergic activity in 
response to orthostatic stress despite reduced peripheral para-
sympathetic activity.
The mechanisms that underlie neurogenic cerebral vasodila-
tion are not fully resolved. Preclinical and clinical evidence sup-
port a role for the cholinergic system; (1) cerebral vessels have 
dense cholinergic innervation (7); (2) stimulation of brainstem 
parasympathetic nuclei, cholinergic nerves, and basal forebrain 
cholinergic nuclei leads to cerebral vasodilation that is potentiated 
by physostigmine and attenuated by atropine (30); and (3) central 
acetylcholinesterase inhibition with physostigmine enhances 
CBF (10). However, several prior studies suggest that nitric oxide 
is the primary cerebral vasodilator and that acetylcholine plays a 
modulating or facilitatory role (31, 32).
While no previous work has examined the effect of physostig-
mine on the cerebrovascular response to orthostatic change, 
pyridostigmine, which does not cross the blood brain barrier, 
improves standing BP in patients with orthostatic hypotension 
due to autonomic failure (33) and attenuates the HR increase in 
patients with postural tachycardia syndrome (34). It is unclear 
FigUre 5 | regional cerebral blood flow response to infusion during last minute of tilt. Anterior cerebral artery (ACA) and middle cerebral artery (MCA) 
cerebral flow velocity (CFV)  response during last minute of 5 min of 60° head up tilt during saline infusion and during Dose 1 and Dose 2 infusion of either 
neostigmine or physostigmine. There were no significant differences between arteries in responses to either dosage or drug. αSignificant effect of drug at that dose 
(P < 0.05).
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whether pyridostigmine affected CVR in these patients since 
CBF was not measured. In contrast, we found no significant 
change in BP or improvement in CBF during tilt in healthy 
controls during peripheral cholinergic activity enhancement 
with neostigmine.
Thus, the role played by cerebral cholinergic vasodilatory 
mechanisms in the features of orthostatic tolerance in autonomic 
failure patients is not known. The present data raise the possibil-
ity that cholinergic activation may enhance CBF. Whether this 
enhancement of CBF could then improve symptoms of orthos-
tatic intolerance in this patient population needs to be examined. 
Further work is required to confirm this in patients and determine 
the dose–response given the narrow therapeutic window.
However, some support for a role for CBF in orthostatic 
intolerance in these patients is provided by examining current 
treatments. Midodrine, which has been found to be effective for 
treating orthostatic intolerance, has also been shown to increase 
CBF in patients with chronic hypotension (35) and spinal cord 
injured patients (36). Similarly, dihydroxyphenylserine has also 
been used to treat orthostatic intolerance and has also been 
found to increase regional CBF (37). Other treatments, such as 
pyridostigmine, a peripheral acetylcholinesterase inhibitor that 
does not cross the blood brain barrier, have not been found to 
affect CBF in animals (38). All of these treatments have also been 
found to increase BP, which may also underlie the increase in CBF. 
Thus, further work in orthostatic intolerance patients examining 
many variables including BP, cardiac output, and CBF would be 
necessary to better understand the role of CBF in orthostatic 
intolerance.
It is interesting that Does 2 of physostigmine resulted in 
higher HRs when upright. We would expect that physostig-
mine should reduce HR since it enhances cholinergic inputs 
to HR control. However, previous work in humans has also 
found that physostigmine infusion results in increased HRs 
(39, 40). The presumed mechanism is central activation of the 
hypothalamic–pituitary–adrenocortical axis as well as increased 
sympathetic outflow to the heart.
Several other explanations for the increase in CBF can be con-
sidered. If participants had impaired autoregulation, an increase 
in MAP during physostigmine infusion could have resulted 
in increased cerebral flow; however, there was no significant 
increase in pressure seen. Also, we did not find any indications 
of impaired autoregulation, which is consistent with evidence 
in primates where direct parasympathetic stimulation results in 
cerebral vasodilation without affecting autoregulation (17).
In addition, middle cerebral artery flow was increased dur-
ing the last minute of tilt during the lowest physostigmine dose 
(Figure 5), suggesting that lower doses of physostigmine could 
be effective during longer periods of orthostatic stress. Further, 
work during longer tilts and testing the effects of lower doses of 
physostigmine on orthostatic tolerance is needed.
One limitation of this study is we were unable to assess sex 
differences due to the small number of participants (six women 
vs two men). Previous research has demonstrated CBF regulation 
may differ between women and men with older women demon-
strating better cerebral autoregulation (41) and young women 
showing greater CBF (42, 43). In addition, CBF appears to be 
affected by time of cycle (44, 45). Since we did not control for time 
of cycle, we cannot examine possible cycle effects on the response. 
Further, work is needed to determine if sex differences and time 
of cycle affect the response to physostigmine.
summary
This work provides the first evidence that increasing central 
cholinergic activity improves the maintenance of CBF in the 
upright posture in healthy participants. These data raise the inter-
esting possibility that use of centrally acting acetylcholinesterase 
inhibitors may improve symptoms in patients with symptomatic 
orthostatic intolerance. Further, work in patient populations is 
necessary to determine whether enhancing central cholinergic 
8Serrador and Freeman Cholinergic Activity Increases CBF
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activity will improve CBF and if this could possibly reduce symp-
toms of orthostatic intolerance.
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